This CAR-NK cell was also used in other strategies to demonstrate that retargeting NK cells with CAR technology is an effective way to overcome the intrinsic resistance of the HER2+ breast cancer cell line MDA-MB-453 to NK cell ADCC [375]. Here, ERBB2 is linked to breast cancer.